Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

4.030 -0.080 (-1.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tvardi Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Unusual volume stocks in Monday's session ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
Which stocks have an unusual volume on Wednesday? 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks ↗
Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response. 
Via Benzinga
News headline image
Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Surges 1%; Fastenal Shares Fall After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? ↗
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review... 
Via Stocktwits
News headline image
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Posts Q2 Net Income Turnaround ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside ↗
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
Via Benzinga
News headline image
This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.